8/102 sources · 2 publishersUpdated Oct 8, 16:04 UTC
Novartis signs up to $7.8 billion licensing deal for Chinese mRNA therapy
Novartis agreed to acquire global rights to an mRNA therapy from Chinese biotech Abogen Biosciences. The agreement includes an upfront payment of $575 million and up to $7.2 billion in milestone payments, for a total potential value of $7.8 billion. The deal is part of a broader wave of Western pharma companies licensing Chinese assets to offset upcoming patent expirations.
Why it matters
The company expects the licensed therapy to help fill the pipeline gap created by patent cliffs, potentially supporting future revenue streams. Analysts note that such licensing arrangements reduce development risk while providing Chinese firms with funding.
Key facts
- 1Novartis will pay $575 million upfront for the global rights to Abogen's mRNA therapy. cnbc.com
- 2The deal includes up to $7.2 billion in milestone payments, bringing total potential consideration to $7.8 billion. cnbc.com
- 3ING estimates Chinese biotech out‑licensing deals will exceed $250 billion in 2026. cnbc.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.